Physician profile
Martha Ellen Hackett
NPI 1467454975
$191.42
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $24.51 · 2022: $13.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $40.94 | 2019 | |
| Shire North American Group INC | $25.93 | 2019 | |
| Sanofi Pasteur INC. | $14.97 | 2019 | |
| Novo Nordisk INC | $13.29 | 2019 | |
| Ibsa Pharma INC. | $13.17 | 2019 | |
| Abbvie INC. | $13.13 | 2022 | |
| Merck Sharp & Dohme LLC | $12.32 | 2020 | |
| Amarin Pharma, INC. | $12.19 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.68 | 2019 | |
| Adlon Therapeutics L.P. | $11.67 | 2019 | |
| Genentech USA, INC. | $11.25 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $10.88 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Hackett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.